12th Mar 2021 13:03
Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Signs GBP470,000 agreement with the UK Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with Covid-19 lateral flow diagnostic tests. The government deal follows Sensyne signing an exclusive licence and development agreement with Excalibur Healthcare Services Ltd to apply MagnifEye for use with lateral flow rapid diagnostic tests.
Chief Executive Paul Drayson says: "We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK's Covid-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study."
Current stock price: 174.90 pence, up 4.1% Friday
Year-to-date change: up 55%
By Paul McGowan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
SENS.L